« Drugs And Their Starting Points |
| Nanoparticles and RNA: Now In Humans »
March 24, 2010
Here's a new article on the concept of "privileged scaffolds", the longstanding idea that there seem to be more biologically active compounds built around some structures than others. This doesn't look like it tells me anything I didn't know, but it's a useful compendium of such structures if you're looking for one. Overall, though, I'm unsure of how far to push this idea.
On the one hand, it's certainly true that some structural motifs seem to match up with binding sites more than others (often, I'd say, because of some sort of donor-acceptor pair motif that tends to find a home inside protein binding sites). But in other cases, I think that the appearance of what looks like a hot scaffold is just an artifact of everyone ripping off something that worked - others might have served just as well, but people ran with what had been shown to work. And then there are other cases, where I think that the so-called privileged structure should be avoided for everyone's good: our old friend rhodanine makes an appearance in this latest paper, for example. Recall this this one has been referred to as "polluting the literature", with which judgment I agree.
+ TrackBacks (0) | Category: Drug Assays | Drug Industry History
POST A COMMENT
- RELATED ENTRIES
- Why Not Share More Bioactivity Data?
- An Anticoagulant Antidote
- Merck's Liptruzet: A Cause For Shame?
- Your Brain Shifts Gears
- Total Synthesis in Print
- Things I Won't Work With: Dimethylcadmium
- Another Germ Theory Victory - Back Pain?
- An Update on Deuterium Drugs